Pharmacyclics raises $57M to advance tyrosine kinase inhibitor for blood cancers
This article was originally published in Scrip
Executive Summary
Cancer developer Pharmacyclics is raising about $57.1 million in gross proceeds from the sale of more than 6.4 million common shares.